svg pci
TRANSCRIPT
![Page 1: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/1.jpg)
Saphenous vein graft intervention
![Page 2: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/2.jpg)
• Svg pathology.
• Natural course.
• Problems in interventions.
• Techniques.
• Procedure related complications.
• Role of stents and supportive medications.
![Page 3: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/3.jpg)
Background
*Ischemic symptoms recur in 4-8% of patients/year following CABG.
*Recurrence of symptoms can be attributed to progression of nativevessel coronary disease (5%/year) and bypass conduit occlusion,particularly SVG failure (7% in week 1; 15-20% in first year; 1-2%/yrduring the first 5-6 years, and 3-5%/yr in years 6-10 postop).
*At 10 years postop, approximately half of all SVG conduits are occludedand only half of the remaining patent grafts are free of significantdisease.
5-10% PCI case volume.
Alexander JH. JAMA 2005; 16;294(19):2446-2454
Widimsky P. Circulation 2004 30;110(22):3418-3423
![Page 4: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/4.jpg)
![Page 5: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/5.jpg)
![Page 6: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/6.jpg)
![Page 7: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/7.jpg)
![Page 8: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/8.jpg)
![Page 9: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/9.jpg)
![Page 10: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/10.jpg)
PATHOPHYSIOLOGY OF SAPHENOUS VEIN GRAFT DISEASE
• Saphenous vein graft disease occurs in three phases:
• (1) early (before hospital discharge) (thrombosis)
• (2) intermediate (1 month to 1 year) (intimal hyperplasia)
• (3) late (beyond 1 year) (atherosclerosis)
![Page 11: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/11.jpg)
Early failure
• Within 30 days
• acute vein graft thrombosis (60%)
• focal stenoses at the proximal or distal anastomotic sites
• kinked grafts.
![Page 12: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/12.jpg)
• Urgent coronary angiography
• Emergency percutaneous intervention if required.
![Page 13: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/13.jpg)
• within 1 to 12 months.
• due to perianastomotic graft stenosis from intimal hyperplasia.
• mid SVG stenosis from fibrous intimalhyperplasia.
• distal anastomotic sites have been treated successfully with balloon dilatation alone
• Stenting deployment compared to balloon angioplasty may further improve outcome.
Intermediate (1 month to 1 year)
![Page 14: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/14.jpg)
• Recurrence of angina at about three months postoperatively is highly suggestive of a distal graft anastomotic lesion and in most cases, lead to evaluation for PCI
![Page 15: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/15.jpg)
Late failure (>1 years after surgery)
• the most common cause of ischemia is the formation of new atherosclerotic plaques which contain– foam cells,
– cholesterol crystals,
– blood elements,
– necrotic debris as in native vessels.
• However, these plaque have less fibrocollagenous tissue and calcification, so they are softer, more friable, of larger size, and frequently associated with thrombus.
![Page 16: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/16.jpg)
Recommendations for PCI With Prior CABG
Class I:Patients with early ischemia (usually within 30 days) after CABG.
(Level of evidence: B)
Class IIa:1. Patients with ischemia occurring 1 to 3 years post-operatively and
preserved LV function with discrete lesions in graft conduits. (Level of evidence: B)
2. Disabling angina secondary to new disease in a native coronary circulation. (If angina is not typical, the objective evidence of ischemia should be obtained). (Level of evidence: B)
3. Patients with diseased vein grafts > 3 years following CABG.(Level of evidence: B)
![Page 17: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/17.jpg)
Recommendations for PCI With Prior CABG
Class III:
1. PCI to chronic total vein graft occlusions.
(Level of evidence: B)
2. Patients with multivessel disease, failure
of multiple SVGs, and impaired LV
function. (Level of evidence: B)
![Page 18: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/18.jpg)
• The status of the LAD and its graft significantly influences the selection process.( because lack of survival benefit of repeat surgery to treat non-LAD ischemia.)
![Page 19: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/19.jpg)
Intervention in degenerated saphenous vein grafts:
• The lesions that are bulky or associated with thrombus are considered to be high-risk.
• The complications include distal embolization, no-reflow, abrupt closure, and perforation.
• So different approaches were devised because there is much to lose from the standpoint of distal embolization causing non-Q MI and increasing long-term mortality.
• In the case of perforation of SVG, usually there is contained perforation rather than cardiac tamponade due to the extrapericardial course of the grafts.
![Page 20: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/20.jpg)
![Page 21: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/21.jpg)
![Page 22: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/22.jpg)
![Page 23: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/23.jpg)
![Page 24: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/24.jpg)
• Prevention of distal embolisation
– Distal protection devices.
– Proximal protection devices.
![Page 25: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/25.jpg)
![Page 26: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/26.jpg)
![Page 27: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/27.jpg)
SAFER Trial – Comparison of
PercuSurge to Routine Stenting in SVG’s
801 Patients Randomized
30 Day MACE
Reduced 42%
P<0.001
Baim et al. Circulation 2002; 105: 1285.
Routine PercuSurge
%
0
20
16.5%
9.6%
![Page 28: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/28.jpg)
The 800 patient multicenter randomized SAFER trial demonstrated a 50% reduction in in-hospital adverse events with PercuSurge distal protection during SVG stenting, when compared to stenting without protection
![Page 29: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/29.jpg)
PercuSurge System
Advantages
Captures smaller
particles and
“humoral” mediators
Disadvantages
Transient occlusion
Long “parking”
segment
Side branches
unprotected
![Page 30: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/30.jpg)
Filter wire
.
![Page 31: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/31.jpg)
![Page 32: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/32.jpg)
In Filter wire-type devices, An emboli entrapment net is mounted on a 0.014" guidewire and expanded distally to the lesion.
Intervention is then performed over the guidewire.
Filters do not block distal blood flow when first deployed unlike occlusive devices.
Dislodged material is caught by the distal filter, which is then closed and retracted only at the end of the procedure.
![Page 33: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/33.jpg)
Fire Trial: Randomized BSC/EPI
Filter vs. PercuSurge in SVGPCI650 patients in 65 sites
Conclusion: FW not inferior to GW
Stone et al. J Am Coll Cardiol 2003; 41: 43A
FW GW
TIMI 3 Flow 95.7% 97.7%
Device Success 95.5% 97.2%
Death 0.9% 0.9%
MI 9.0% 10.0%
QMI 0.9% 0.6%
30 day MACE 9.9% 11.6%
![Page 34: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/34.jpg)
![Page 35: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/35.jpg)
![Page 36: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/36.jpg)
PROXIMAL OCCULUSION
DEVICES
These devices occlude flow into the
vessel using a balloon on the tip of
catheter
Two proximal occulusion catheters are in
use:
Proxis catheter
Kerberos embolic protection system
![Page 37: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/37.jpg)
These have potential advantage of providing embolic protection even before the first wire crosses the lesion.
Proxis In Vessel
![Page 38: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/38.jpg)
![Page 39: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/39.jpg)
Benefits to Proximal Protection
Nothing crosses the lesion prior to protection
Protection of main vessel and side branches
Captures large and small particles
Can handle large embolic loads
![Page 40: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/40.jpg)
• Is there a role for 2b3a inhibitors in SVG interventions ?
![Page 41: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/41.jpg)
![Page 42: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/42.jpg)
![Page 43: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/43.jpg)
![Page 44: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/44.jpg)
SVG PCI
Recommendation COR LOE
Embolic protection device use when technically feasible
I B
GP IIb/IIIa inhibitors III - No Benefit
B
PCI for chronic SVG occlusions III - Harm C
GNL 2011
![Page 45: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/45.jpg)
![Page 46: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/46.jpg)
![Page 47: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/47.jpg)
![Page 48: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/48.jpg)
![Page 49: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/49.jpg)
![Page 50: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/50.jpg)
![Page 51: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/51.jpg)
![Page 52: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/52.jpg)
![Page 53: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/53.jpg)
![Page 54: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/54.jpg)
![Page 55: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/55.jpg)
No Reflow Pharmacological Therapy
Recommendation COR LOE
Administration of an intracoronary vasodilator (adenosine, calcium channel blocker, or nitroprusside) to treat PCI-related no-reflow that occurs during primary or elective PCI
IIa B
GNL 2011
![Page 56: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/56.jpg)
![Page 57: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/57.jpg)
![Page 58: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/58.jpg)
![Page 59: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/59.jpg)
![Page 60: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/60.jpg)
![Page 61: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/61.jpg)
• Do DES offer an advantage over BMS in SVG
![Page 62: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/62.jpg)
![Page 63: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/63.jpg)
![Page 64: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/64.jpg)
![Page 65: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/65.jpg)
![Page 66: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/66.jpg)
![Page 67: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/67.jpg)
• The data at present indicate that DESs in SVGs are safe; the occurrence of death or MI is equal or less than with BMSs, and there is no difference in stent thrombosis.
• Use of DES has been associated with a reduction in angiographic restenosis and TLR in patients undergoing SVG PCI.
• Choosing DESs over BMSs for the treatment of severe focal SVG stenoses must depend on the assurance of reliable dual antiplatelet therapy and be favoured in SVGs < 3.5 mm in diameter and in patients at high risk for restenosis (long lesions, diabetics).
![Page 68: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/68.jpg)
![Page 69: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/69.jpg)
![Page 70: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/70.jpg)
![Page 71: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/71.jpg)
![Page 72: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/72.jpg)
![Page 73: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/73.jpg)
![Page 74: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/74.jpg)
![Page 75: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/75.jpg)
CONCLUSION• SVG PCI is complicated by atheroembolic myocardial infarction and
high subsequent cardiac events due to restenosis and progressive vein graft disease.
• However, embolic protection strategies documented to be beneficial across the entire range of risk strata are markedly underutilized.
• Will physician education be sufficient to change this practice?
• Are DESs sufficiently effective in SVGs to warrant the increased cost associated with their use?
• Is one DES more effective than others?
![Page 76: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/76.jpg)
• And finally, can disease progression in non target sites be retarded?
• Will the use of “plaque sealing” of moderate SVG lesions by DES implantation, which appeared promising in a pilot trial, be tested in the multicenter study required to corroborate these findings?
• In the future of bypass graft intervention, there are more questions than answers.
![Page 77: Svg pci](https://reader031.vdocument.in/reader031/viewer/2022020123/55af4c2d1a28abfc2d8b45f2/html5/thumbnails/77.jpg)
THANK YOU